文献速递中枢神经肿瘤放疗放疗物理与技术

脑转移瘤大分割放疗后假性进展与肿瘤复发的剂量学及临床分析

Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases.
PubMed 文献 · Radiat Oncol · 2023-02-14

本研究回顾性分析2009年3月至2019年10月本中心123例脑转移瘤大分割放疗后病灶增大的患者,评估假性进展与肿瘤复发的预测因素。76例(61.8%)判定为假性进展,47例(38.2%)判定为肿瘤复发;肿瘤复发相关因素包括大体肿瘤体积≥6 cc、生物有效剂量<60 Gy、靶区覆盖率<96%及未接受靶向治疗,基于这些因素建立的列线图模型在训练队列和验证队列的AUC分别为0.730和0.967。

要点

  • 脑转移瘤大分割放疗后病灶增大者中61.8%为假性进展、38.2%为肿瘤复发。
  • 肿瘤复发相关因素:大体肿瘤体积≥6 cc、生物有效剂量<60 Gy、靶区覆盖率<96%、未接受靶向治疗。
  • 列线图模型训练队列AUC 0.730、验证队列AUC 0.967。

核心结论

  • 基于增强脑磁共振的大分割放疗临床与剂量学特征有助于区分脑转移瘤大分割放疗后的假性进展与肿瘤复发。
  • 大体肿瘤体积、生物有效剂量、靶区覆盖率及是否接受靶向治疗是与肿瘤复发发生相关的因素,列线图可有效评估个体风险。

研究设计与样本

  • 回顾性分析本中心2009年3月至2019年10月123例大分割放疗后脑转移瘤增大的患者,分析基线临床特征、放疗计划参数及放疗前后增强磁共振。
  • 采用Logistic回归比较组间差异,以P<0.05且与复发相关的独立危险因素建立列线图预测模型,经Bootstrap重复抽样验证,并在2019年10月至2021年12月的内部队列(n=23)中验证。

主要发现

  • 中位随访时间68.4个月(范围8.9-146.2个月)。
  • 76例(61.8%)患者判定为假性进展,47例(38.2%)判定为肿瘤复发。
  • 假性进展与肿瘤复发的中位时间分别为18.3个月(四分位距9.4-27.8个月)和12.9个月(四分位距8.7-19.6个月)。
  • 与肿瘤复发相关的变量包括:大体肿瘤体积≥6 cc、生物有效剂量<60 Gy、靶区覆盖率<96%及未接受靶向治疗。
  • 训练队列和验证队列的曲线下面积分别为0.730和0.967。

关键数值与推荐

  • 肿瘤复发相关因素:大体肿瘤体积≥6 cc、生物有效剂量<60 Gy、靶区覆盖率<96%、未接受靶向治疗(P<0.05)。
  • 列线图模型训练队列AUC 0.730、验证队列AUC 0.967。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main challenge in follow-up duration of patients with brain metastases after stereotactic radiotherapy is to distinguish between pseudo-progression and tumor recurrence. The objective of this study is to retrospectively analyze the predictive factors. METHODS: The study included 123 patients with enlarged brain metastases after hypo-fractionated radiotherapy in our center from March 2009 to October 2019, and the baseline clinical features, radiotherapy planning parameters, and enhanced magnetic resonance imaging before and after radiation therapy were analyzed. Logistic regression was performed to compare the differences between groups. Independent risk factors with P < 0.05 and associated with recurrence were used to establish a nomogram prediction model and validated by Bootstrap repeated sampling, which was validated in an internal cohort (n = 23) from October 2019 to December 2021. RESULTS: The median follow-up time was 68.4 months (range, 8.9-146.2 months). A total of 76 (61.8%) patients were evaluated as pseudo-progression, 47 patients (38.2%) were evaluated as tumor recurrence. The median time to pseudo-progression and tumor recurrence were 18.3 months (quartile range, 9.4-27.8 months) and 12.9 months (quartile range, 8.7-19.6 months) respectively. Variables associated with tumor recurrence included: gross tumor volume ≥ 6 cc, biological effective dose < 60 Gy, target coverage < 96% and no targeted therapy. The area under curve values were 0.730 and 0.967 in the training and validation cohorts, respectively. Thirty-one patients received salvage therapy in the tumor recurrence group. The survival time in pseudo-progression and tumor recurrence groups were 66.3 months (95% CI 56.8-75.9 months) and 39.6 months (95% CI 29.2-50.0 months, respectively; P = 0.001). CONCLUSIONS: Clinical and dosimetry features of hypo-fractionated radiation therapy based on enhanced brain magnetic resonance can help distinguish pseudo-progression from tumor recurrence after hypo-fractionated radiotherapy for brain metastases. Gross tumor volume, biological effective dose, target coverage, and having received targeted therapy or not were factors associated with the occurrence of tumor recurrence, and the individual risk could be estimated by the nomogram effectively.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang S, Ma Y, Xu Y, et al. Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases. Radiat Oncol. 2023. PMID: 36788610. doi:10.1186/s13014-023-02214-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。